Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms

Despite the emergence of JAK inhibitors, there is a need for disease-modifying treatments for Philadelphia-negative myeloproliferative neoplasms (MPNs). JAK inhibitors ameliorate symptoms and address splenomegaly, but because of the heterogeneous contributors to the disease process, JAK inhibitor mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, Jason B., Stein, Brady L., McMahon, Brandon, Giles, Francis J., Platanias, Leonidas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739416/
https://www.ncbi.nlm.nih.gov/pubmed/26870834
http://dx.doi.org/10.1016/j.ebiom.2016.01.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739416/
https://www.ncbi.nlm.nih.gov/pubmed/26870834
http://dx.doi.org/10.1016/j.ebiom.2016.01.010

Ejemplares similares